Clinical trial · no report yet · Phase 3
PACIFIC-4
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
- NCT03833154 ↗
- Active, not recruiting
- AstraZeneca
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 23 | |
| Podcasts | 6 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab With Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) Osimertinib Following SBRT, a Single Arm Cohort for Patients With Unresected Stage I/II, Lymph Node Negative NSCLC Harboring a Sensitizing EGFR Mutation
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Durvalumab; Placebo; (Osimertinib cohort, single-arm, open-label separate cohort)
- Arms
- SoC SBRT + Durvalumab Therapy (Main Cohort) · Experimental
- SoC SBRT + Placebo Therapy (Main Cohort) · Placebo comparator
- SoC SBRT + Osimertinib Therapy (Osimertinib cohort, single-arm, open-label separate cohort) · Experimental
- Enrollment
- 724
- Primary outcomes
- Progression-Free Survival (PFS) assessed by Blinded Independent Central Review (BICR) according to RECIST 1.1 in subpopulation of patients with Stage I/II NSCLC
- 4-year Progression-Free Survival (4y-PFS) by ICR according to RECIST 1.1 criteria
- Sponsor
- AstraZeneca
- Start
- Mar 6, 2019
- Primary completion
- Oct 31, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT03833154 · updated Jul 20, 2026